Genmab

Genmab A/S is a leading international biotechnology company specializing in the discovery and development of innovative antibody-based therapies for cancer and other serious diseases. Established in 1999 and headquartered in Copenhagen, Denmark, the company has built a strong global reputation for advancing next-generation antibody technologies and precision medicine. Genmab focuses on creating differentiated biologic therapies that improve treatment outcomes while addressing unmet medical needs in oncology and immunology.

The company’s proprietary technology platforms, including DuoBody®, HexaBody®, and HexElect®, support the development of advanced monoclonal antibodies and bispecific antibody therapies. These technologies have enabled collaborations with several major pharmaceutical companies and contributed to the successful commercialization of multiple innovative cancer treatments. Genmab maintains a robust clinical pipeline spanning hematologic malignancies, solid tumors, autoimmune diseases, and emerging therapeutic areas.

With research and development operations across Europe, North America, and Asia-Pacific, Genmab continues to invest heavily in scientific innovation, clinical research, and strategic partnerships. The company follows strict international quality standards and emphasizes ethical business practices, sustainability, and patient-focused healthcare solutions. Through continuous scientific advancement and global collaboration, Genmab has established itself as one of the world’s premier antibody-focused biotechnology companies, delivering transformative therapies that improve the lives of patients worldwide.